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I will address three major issues that are the main benefits from using protease inhibitor (PI)-sparing regimens, such as efficacy of antiviral activity, metabolic side effects, and adherence. Anti-HIV efficacy is at least equal, and perhaps sometimes controversially superior to PIs because of fewer metabolic side effects, which results in better tolerance. Less controversial is the idea that PI-sparing regimens improve adherence because of decreased complexity, lower pill burden, and options for once-daily therapy.
Anti-HIV activity
There are many studies that compared PI-sparing to PIbased regimens. The DMP-006 study compared efavirenz (EFV) + Combivir (zidovudine (ZDV) + lamivudine (3TC)), to an indinavir (IDV) + Combivir, and to an EFV + IDV regimen. The as-treated (AT) and intent-to-treat (ITT) analyses showed that EFV did as well, if not better, in anti-HIV activity than IDV with Combivir. This suggested that PIsparing regimens could match a PI-based regimen of the day. Data from Figure 1 show the first 48 weeks of anti-HIV treatment. Figure 2 shows the same type of activity after two years of therapy, in getting individuals to an undetectable level of plasma viremia and its durability, with the PI-sparing regimen EFV and Combivir. Eighty percent of individuals at 96 weeks maintained their response to therapy. There was significant decline in the group that received PIs.
Another study compared a nelfinavir (NFV)-based regimen to a nevirapine (NVP)-based regimen. It was one of the first studies that actually compared PI given twice daily to a PI-sparing regimen. In Figure 3 , the ITT and AT analyses show the PI-sparing regimen performing at least as well, if not slightly better, than the PI-based regimen given twice daily.
More recently, there were comparisons between abacavir (ABC)-based regimens or Trizivir (ZDV + 3TC + ABC), and twice-daily IDV + Combivir regimen. The ABC-based regimen was comparable in virologic outcome to the PI-based regimen. One of the controversies about these data and use of all nucleoside regimens has been whether performance is maintained in individuals who have lower CD4 cell counts and higher viral loads. This showed that the CD4 cell count rises were similar in the ABC and IDV arms, which has been true of the other studies.
What about individuals with higher viral loads? When you look at ITT analysis, Trizivir looked significantly better in individuals with lower viral loads up to 100,000 copies/mL. There was not much difference in individuals with greater than 100,000 copies/mL. The ITT analysis may have been biased, by presuming outcomes for individuals who drop out of the study, and so we were interested in looking at both the ITT as well as the AT analyses. Looking at the AT analysis, and at individuals with higher viral loads, the PI-based regimen tended to be better than the ABC. There were concerns about whether this particular PIsparing regimen can be used in individuals with higher viral loads, and about the problem of using IDV-based regimens. We are currently moving away from regimens that require pills three times a day with food restrictions toward comparison of the Trizivir regimen with more commonly used PI-based regimens.
A more recent GlaxoSmithKline study compared Trizivir to Combivir + NFV twice daily, as well as stavudine (d4T) + 3TC + NFV. It looked at individuals with viral loads from 1,000 to 200,000 copies/mL, and stratified them on whether they were less than or greater than 100,000 copies/mL. The study was originally designed to focus on women, although it later recruited men to increase the study population. It remains important because it contained a greater proportion of women than in other studies. The study did not compare virologic outcomes from these three groups, but looked at some of the differences in metabolic complications. The 48week data in Figure 4 were the observed ITT analysis, and looked like the AT analysis. The treatment groups appeared similar in outcome, showing regimens are comparable. In individuals with higher viral load, from 100,000 to 200,000 copies/mL, the proportions with viral load suppression less than 50 copies/mL appeared similar in the Combivir + NFV, and Trizivir treatment groups. The CD4 cell count rise was similar across the three groups.
Although the study made no comparison to a PI-based regimen, it led to the idea of the potential potency and efficacy of using once-daily combinations with didanosine (ddI), 3TC, and EFV. Recent data showed eighty percent of individuals responding at 48 weeks with plasma viremia less than 50 copies/mL, but no differences with individuals who had viral loads greater or less than 100,000 copies/mL.
Another PI-sparing regimen that has gained attention is the "compact QUAD." A regimen of Combivir, ABC, and EFV may address questions about using a Trizivir or a triple nucleoside regimen in individuals with higher viral loads or lower CD4 cell counts when a PI is not initially desirable. This may be an interesting option because it adds to activity of Trizivir without additional problems with multiple doses. A current study in the AIDS Clinical Trial Group (ACTG) compares this regimen with Trizivir alone, versus a regimen of Combivir and EFV. This leads to questions about whether some activity is gained over Trizivir alone, and whether anything is gained with this regimen rather than with EFV + Combivir.
Side effects
The second issue when looking at the benefits of PIsparing regimens deals with metabolic side effects. Figure 5 shows that a combination of both PIs and nucleosides contributes to lipodystrophy syndrome. The nucleosides play a bigger role in fat atrophy and lactic acidosis, whereas PIs appear to be more involved in cholesterol and triglyceride elevation, insulin resistance, and fat accumulation. Figure 6 shows common metabolic side effects associated with particular drugs. Nucleosides are associated with lipoatrophy, lactic acidosis, and some bone abnormalities. Some studies controversially suggested that nucleosides contributed to osteoporosis and osteopenia. There are not many metabolic side effects in the non-nucleoside class, but clearly EFV contributes to lipid problems. PIs have been implicated in fat accumulation, serum lipids, diabetes, and controversially with bony abnormalities. Some studies showed osteoporosis that resulted from HIV disease improves in individuals on PIs. The study comparing Trizivir to Combivir + NFV, and d4T + 3TC + NFV looked at metabolic complications, particularly lipid issues. Figure 7 shows the mean lowdensity lipoprotein (LDL) change in individuals from baseline at 48 weeks. The NFV-based arms show increases in LDL, whereas there are slight decreases in the individuals who receive Trizivir. Not only was there a difference in the triglycerides between the NFV-based regimen and the Trizivir, there actually seems to be a significant difference within the NFV-based regimen between the d4T arm and the ZDV arm. This is not well understood, and requires more study. There seems to be a trend of more elevated cholesterol and triglycerides with PI-based regimens than with a triple nucleoside regimen.
The study also addressed whether individuals have elevated lactate levels or lactic acidosis with triple nucleosides, as opposed to two nucleosides in combination with another class. It measured lactate levels of men and women over a period of 48 weeks. Women seemed to be at greater risk for elevated lactate issues, and some progressed to lactic acidosis. Overall, there were minor elevations for individuals on triple nucleosides, and for those on ZDV + 3TC + NFV. Most elevations occurred with the d4T-based regimen. This does not suggest that there are more lactate problems with three nucleosides than with two nucleosides.
Other studies looked at switching people away from PIs to regimens based on ABC, EFV, or NVP. Data in Figure  8 show improvement with triglycerides and LDLs when individuals switched to any of the three regimens. The high-density lipoprotein (HDL) levels suggest greatest improvement when switching from the PI to the nonnucleosides, and a lesser decline when switching to triple nucleosides. In triglycerides, the greatest decline was seen when switching to NVP.
What about concerns that PIs may be implicated with coronary heart disease through lipids and diabetes? Are we seeing excess cardiac disease in HIV-infected patients as a result of PIs or any type of HAART? Two recent abstracts were updates, particularly data from the Hobbs cohort. They assessed cardiac events in almost 6,000 patients, and found 15 myocardial infarctions (MIs). Thirteen were on PIs and two were on non-PIs, for an odds ratio of 4:9. This is a small number of events, and a short follow-up time. We are likely to see more events as individuals have a prolonged period of time with risk factors, particularly elevated lipids. The analysis also did not consider prior therapy. There could have been individuals who were not currently on PIs, although they had previous experience with PIs not included in that class. This also does not count for prescribing biases.
An updated Kaiser Permanente database study focused only on MIs among 4,000 HIV-infected patients, and 40,000 patients with no HIV disease. The study found 72 coronary events, and 47 MIs. There was no significant difference between individuals with or without HIV, although a trend seemed to suggest individuals with HIV had more events. There also seemed to be no differences between individuals on PIs and non-PIs.
Adherence
What about the benefit of improved adherence with PI-sparing regimens? A high level of adherence is critical to successful therapy, but not always attained by individuals. Figure 9 refers to the early PI era with regimens that required dosing several times a day. Nowadays this might be a little bit different as suggested by studies using triple nucleosides. Clearly, a very high level of adherence, greater than 95 percent, is necessary for successful antiretroviral therapy.
This point is reinforced with data from NFV-treated patients in Figure 10 . Lesser adherence is accompanied with an increase in the plasma HIV RNA levels, or higher viral loads. Resistance mutations occur with individuals who take most, but not all, of their medications, rather than with individuals who take their medications very little, if at all.
What are some of the characteristics of a complex regimen with doses more than twice a day? Studies about hypertension showed that regimens with dosing three or more times a day impaired adherence more than regimens with twice-daily dosing. There are no clear studies showing that once-daily dosing is better than twice-daily dosing.
Clearly, pill burden is important. Lower adherence has been associated with taking more than four drugs, along with food and water restrictions and special storage requirements that accompany PI therapy. Figure 11 demonstrates a recent meta-analysis of the virologic impact of pill burden by John A. Bartlett, from Duke University Medical Center in Durham, North Carolina. Bartlett's group looked at numerous studies that used PIs and triple nucleosides, as well as non-nucleoside regimens. The analysis showed the proportion of individuals who respond decreases as the number of pills increases.
There has been an important transition from taking many pills during the pre-HAART period, to taking a single pill such as ddI and EFV. Benefits were clear in moving away from complex regimens with time restrictions for IDV, 3TC, and ZDV, to simpler regimens such as Combivir + ABC, or Trizivir.
Is there a difference in patient response based on pill burdens and simplicity of medications? A comparison between ABC + Combivir, and IDV + Combivir shows the self-reported adherence of patients over a onemonth period of time. Only 46 percent of the individuals had 100 percent adherence. In the Trizivir arm, there were twice as many adherents, when compared to the IDV + Combivir arm. The number of individuals who had greater than 95 percent adherence was good. Clearly, a simpler regimen results in better adherence in the patient.
In conclusion, lower pill burden is a major benefit of PIsparing regimens, compared to a PI-based regimen, leading to increased simplicity and better adherence. A PI-sparing regimen may also have superior anti-HIV efficacy, and fewer long-term metabolic side effects, particularly in relation to lipid abnormalities. It remains to be seen whether these advantages may be balanced by acute toxicities such as hepatitis or drug rash and hypersensitivity. ■
